Skip to content

Towards Optimal Screening and Management of Coronary Artery Disease in Diabetes: TOSCANA Study

Towards Optimal Screening and Management of Coronary Artery Disease in Diabetes: TOSCANA Study

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05314140
Acronym
TOSCANA
Enrollment
0
Registered
2022-04-06
Start date
2025-01-01
Completion date
2028-01-01
Last updated
2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Diabetes Mellitus

Keywords

Coronary artery calcium score, Heart failure risk factors, Prevention, Guidelines

Brief summary

There are currently only few data on the coronary artery calcium score in patient with diabetes in France, and the diagnostic and therapeutic attitudes towards a high coronary artery calcium score are not standardized and depend on clinical practices, which may vary from one center to another. The proposed multicenter prospective study would provide a better understanding of the epidemiological particularities of the coronary artery calcium score in French diabetics, refine the indications for better performance of the examination, and compare attitudes when this score is high.

Detailed description

The prevalence of coronary heart disease in patient with diabetes varies according to the patient's age, the duration of the diabetes, the coexistence of other heart disease risk factors, but also the type of diagnostic used to detect it. In addition, clinical symptoms are often lacking in diabetic patients. The latest recommendations from the European Society of Cardiology in 2018 propose a graduation of cardiovascular risk into 3 categories according to the presence of cardiovascular disease, other target organ damage, the duration of diabetes and the coexistence of other heart disease risk factors. The use of imaging can be considered to refine the cardiovascular risk stratification , such as detection of carotid plaque (class IIa), coronary artery calcium score (class IIb) or even the coronary scanner or ischemia tests (class IIb ). In a much more pragmatic and operational way, the French Society of Cardiology and the Francophone Society of Diabetology very recently published a consensus document, proposing a cardiovascular risk stratification based on clinical elements, the existence of other cardiovascular risk factors and target organ damage risk factors, and the use of the coronary artery calcium score to stratify in particular patients qualified as high risk.

Interventions

DIAGNOSTIC_TESTCoronary artery calcium score evaluation

The evaluation of the coronary artery calcium score will be performed with chest CT scan

Sponsors

French Cardiology Society
Lead SponsorOTHER
Novo Nordisk A/S
CollaboratorINDUSTRY
CEBIMER
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Coronary asymptomatic patient * Patient with type 2 diabetes and aged 50 to 70 or - Patient with type 2 diabetes for more than 10 years and aged 18 to 50 or - Patient with type 1 diabetes for more than 20 years and aged \> 35 * Coronary artery calcium score evaluation planned

Exclusion criteria

* Patients who already have a clinical history of coronary disease * Patients with other peripheral arterial disease * Patients with clinical suspicion of coronary artery disease * Patients with progressive cancer * Patients with serious chronic conditions with an estimated life expectancy \< 3 years. * Pregnant, lactating, or pre-menopausal women without a recent negative pregnancy test available. * Patients under guardianship or curator or placed under justice safeguard * Patients who do not benefit from the social security scheme, or any equivalent scheme * Patients refusing or being linguistically or psychologically unable to sign the informed consent form Participation in another biomedical research protocol is permitted

Design outcomes

Primary

MeasureTime frameDescription
Proportions of diabetic patients with high coronary artery calcium scoreday 1Number of patient with diabetes having a coronary artery calcium score higher than 400

Secondary

MeasureTime frameDescription
Proportion of patients having a coronary exploration6 monthsNumber of patient with high coronary artery calcium (\>400) score having a coronary exploration compared with patient with low coronary artery calcium score (\<400)
Proportion of patients having a myocardial revascularization3 monthsNumber of patient with high coronary artery calcium score (\>400) having a myocardial revascularization compared with patient with low coronary artery calcium score (\<400)
Description of adverse events regarding to the coronary artery calcium score6 months / 12 months / 18 months / 24 months / 30 months / 36 months / 42 months / 48 monthsCalculation of number and type of cardiovascular adverse event within patient with high coronary artery calcium score (\>400) or low coronary artery calcium score (\<400)

Countries

France

Contacts

PRINCIPAL_INVESTIGATORVictor ABOYANS, MD

University Hospital, Limoges

STUDY_DIRECTORTessa BERGOT

Société Française de la Cardiologie

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026